{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T04:18:47Z","timestamp":1766290727396,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pheochromocytoma (PHEO) and paraganglioma (PGL) are rare neuroendocrine tumors releasing catecholamines. Metastatic pheochromocytomas\/paragangliomas (PPGLs) occur in about 5\u201326% of cases. To date, the management of patients affected by metastatic disease is a challenge in the absence of guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The aim of this study was to evaluate the overall survival (OS) and the progression-free survival (PFS) in metastatic PPGLs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical data of 20 patients referred to the Careggi University Hospital (Florence, Italy) were retrospectively collected. Follow-up ranged from 1989 to 2019. Site and size of primary tumor, biochemical activity, genetic analysis and employed therapies were considered. Data were analyzed with SPSS version 27.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine PHEOs (45%) and 11 PGLs (55%) were enrolled. Median age at diagnosis was 43.5\u00a0years [30\u201355]. Mean follow-up was 104.6\u2009\u00b1\u200989.3\u00a0months. Catecholamines were released in 70% of cases<jats:italic>.<\/jats:italic> An inherited disease was reported in 50% of patients. OS from the initial diagnosis (OSpt) and from the metastatic appearance (OSmtx) were lower in older patients (OSpt <jats:italic>p<\/jats:italic>\u2009=\u20090.028; OSmtx <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), abdominal PGLs (OSpt <jats:italic>p<\/jats:italic>\u2009=\u20090.007; OSmtx <jats:italic>p<\/jats:italic>\u2009=\u20090.041), larger tumors (OSpt <jats:italic>p<\/jats:italic>\u2009=\u20090.008; OSmtx <jats:italic>p<\/jats:italic>\u2009=\u20090.025) and sporadic disease (OSpt <jats:italic>p<\/jats:italic>\u2009=\u20090.013; OSmtx <jats:italic>p<\/jats:italic>\u2009=\u20090.008).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data showed that older age at the initial diagnosis, sympathetic extra-adrenal localization, larger tumors and wild-type neoplasms are related to worse prognosis. Notably, the employed therapies do not seem to influence the survival of our patients. At present, effective treatments for metastatic PPGLs are missing and a multidisciplinary approach is indispensably required.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-021-01629-x","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T18:02:45Z","timestamp":1625508165000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management and outcome of metastatic pheochromocytomas\/paragangliomas: a monocentric experience"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-5526","authenticated-orcid":false,"given":"G.","family":"De Filpo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rastrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ercolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Luconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Canu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"issue":"1","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40618-020-01344-z","volume":"44","author":"G De Filpo","year":"2021","unstructured":"De Filpo G, Maggi M, Mannelli M, Canu L (2021) Management and outcome of metastatic pheochromocytomas\/paragangliomas: an overview. J Endocrinol Invest 44(1):15\u201325. https:\/\/doi.org\/10.1007\/s40618-020-01344-z","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","volume":"28","author":"AK Lam","year":"2017","unstructured":"Lam AK (2017) Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol 28(3):213\u2013227. https:\/\/doi.org\/10.1007\/s12022-017-9484-5","journal-title":"Endocr Pathol"},{"key":"1629_CR3","unstructured":"Tischler AS, de Krijger RR (2017) Phaeochromocytoma. In WHO Classification of Tumors of Endocrine Organs, 4th ed.; Lloyd RV, Osamura RY, Kloppel G, Eds.; IARC Press: Lyons, France, pp. 183\u2013189. ISBN 978\u201392\u2013832\u20134493\u20136."},{"issue":"3","key":"1629_CR4","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C (2014) Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111\u2013R122. https:\/\/doi.org\/10.1530\/EJE-14-0113","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1210\/jc.2006-1544","volume":"92","author":"T Scholz","year":"2007","unstructured":"Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H (2007) Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92(4):1217\u20131225. https:\/\/doi.org\/10.1210\/jc.2006-1544","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"E724","DOI":"10.3390\/cancers11050724","volume":"11","author":"A Angelousi","year":"2019","unstructured":"Angelousi A, Peppa M, Chrisoulidou A, Alexandraki K, Berthon A, Faucz FR, Kassi E, Kaltsas G (2019) Malignant pheochromocytomas\/paragangliomas and ectopic hormonal secretion: a case series and review of the literature. Cancer (Basel) 11(5):E724. https:\/\/doi.org\/10.3390\/cancers11050724","journal-title":"Cancer (Basel)"},{"issue":"4","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1210\/er.2002-0013","volume":"24","author":"EL Bravo","year":"2003","unstructured":"Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24(4):539\u2013553. https:\/\/doi.org\/10.1210\/er.2002-0013","journal-title":"Endocr Rev"},{"key":"1629_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1583::AID-CNCR28>3.0.CO;2-#","volume":"86","author":"HM Brown","year":"1999","unstructured":"Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR (1999) Predicting metastasis of pheochromocytoma using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behaviour. Cancer 86:1583\u20131589","journal-title":"Cancer"},{"issue":"10","key":"1629_CR9","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1210\/jc.2007-0709","volume":"92","author":"L Amar","year":"2007","unstructured":"Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92(10):3822\u20133828. https:\/\/doi.org\/10.1210\/jc.2007-0709","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","volume":"19","author":"P Jimenez","year":"2017","unstructured":"Jimenez P, Tatsui C, Jessop A, Thosani S, Jimenez C (2017) Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress. Curr Oncol Rep 19(12):83. https:\/\/doi.org\/10.1007\/s11912-017-0643-0","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"1629_CR11","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, Iniguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 102(9):3296\u20133305. https:\/\/doi.org\/10.1210\/jc.2017-00992","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1210\/jc.2018-01968","volume":"104","author":"S Hescot","year":"2019","unstructured":"Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, de la Fouchardi\u00e8re C, Valdes N, Riccardi F, Do Cao C, Bertherat J, Goichot BF, Drui D, Canu L, Niccoli P, Laboureau S, Tabarin A, Leboulleux S, Calsina B, Lib\u00e9 R, Faggiano A, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers JLM, Fassnacht M, Robledo M, Borget I, Baudin E for the European Network for the Study of Adrenal Tumors (ENS@T) (2019) Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab 104(6):2367\u20132374. https:\/\/doi.org\/10.1210\/jc.2018-01968","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JWM, Siegert G, Borstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K (2012) Plasma methoxytiramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48(11):1739\u20131749. https:\/\/doi.org\/10.1016\/j.ejca.2011.07.016","journal-title":"Eur J Cancer"},{"issue":"3","key":"1629_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717\u2013725. https:\/\/doi.org\/10.1210\/jc.2010-1946","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MED.0000000000000476","volume":"26","author":"O Hamidi","year":"2019","unstructured":"Hamidi O (2019) Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr Opin Endocrinol Diabetes Obes 26(3):146\u2013154. https:\/\/doi.org\/10.1097\/MED.0000000000000476","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"1629_CR16","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboullex S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Foucharidi\u00e8re C, Lib\u00e9 R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E, French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-Reseau National des Tumeurs Endocrines and COrtico-MEdullo Tumeurs Endocrines network (2013) One-year progression-free survival of therapy-na\u00efve patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98(10):4006\u20134012. https:\/\/doi.org\/10.1210\/jc.2013-1907","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C (2018) Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or paraganglioma. Ann Surg 268(1):172\u2013178. https:\/\/doi.org\/10.1097\/SLA.0000000000002195","journal-title":"Ann Surg"},{"issue":"8","key":"1629_CR18","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1210\/jc.2008-2697","volume":"94","author":"K Nomura","year":"2009","unstructured":"Nomura K, Kimura H, Shimuzu S, Kodama H, Okamoto T, Obara T, Tokano K (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94(8):2850\u20132856. https:\/\/doi.org\/10.1210\/jc.2008-2697","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","volume":"8","author":"S Asai","year":"2017","unstructured":"Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M (2017) Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Horm Cancer 8(2):108\u2013118. https:\/\/doi.org\/10.1007\/s12672-017-0284-7","journal-title":"Horm Cancer"},{"issue":"11","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, D\u00e9andreis D, Borget I, Loriot C, Chougnet C, Letouz\u00e9 E, Young J, Amar L, Bertherat J, Lib\u00e9 R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135(11):2711\u20132720. https:\/\/doi.org\/10.1002\/ijc.28913","journal-title":"Int J Cancer"},{"key":"1629_CR21","doi-asserted-by":"publisher","unstructured":"Jimenez C, Fazeli S, Roman-Gonzalez A (2020) Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer 1:ERC-20\u20130043.R2. https:\/\/doi.org\/10.1530\/ERC-20-0043.","DOI":"10.1530\/ERC-20-0043"},{"issue":"1","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2017","unstructured":"Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, Hallemeir CL (2017) External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3(1):25\u201329. https:\/\/doi.org\/10.1016\/j.adro.2017.11.002","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"1629_CR23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/cancers11071018","volume":"11","author":"C Jimenez","year":"2019","unstructured":"Jimenez C, Erwin W, Chasen B (2019) Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine. Cancers (Basal) 11(7):1018. https:\/\/doi.org\/10.3390\/cancers11071018","journal-title":"Cancers (Basal)"},{"issue":"4","key":"1629_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","volume":"115","author":"K Nastos","year":"2017","unstructured":"Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, Khoo B (2017) Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive pheochromocytomas\/paragangliomas. J Surg Oncol 115(4):425\u2013434. https:\/\/doi.org\/10.1002\/jso.24553","journal-title":"J Surg Oncol"},{"issue":"1","key":"1629_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1677\/erc-10-0211","volume":"18","author":"G Eisenhofer","year":"2010","unstructured":"Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, Mannelli M, Friberg P, Grebe SK, Timmers HJ, Bornstein SR, Lenders JW (2010) Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 18(1):97\u2013111. https:\/\/doi.org\/10.1677\/erc-10-0211","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1629_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cncr.10252","volume":"94","author":"JH Lee","year":"2002","unstructured":"Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, Hoffman HT, American College of Surgeons Commission on Cancer; American Cancer Society (2002) National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 94(3):730\u2013737. https:\/\/doi.org\/10.1002\/cncr.10252","journal-title":"Cancer"},{"issue":"2","key":"1629_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/joim.12869","volume":"285","author":"A Muth","year":"2019","unstructured":"Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, Sandstedt J, Tengvar M, Tham E (2019) Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med 285(2):187\u2013204. https:\/\/doi.org\/10.1111\/joim.12869","journal-title":"J Intern Med"},{"issue":"6","key":"1629_CR28","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine Society (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"1629_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","volume":"100","author":"S Pillai","year":"2016","unstructured":"Pillai S, Gopalan V, Smith RA, Lam AKY (2016) Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol 100:190\u2013208. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1629_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/eje.0.1470085","volume":"47","author":"E van der Harst","year":"2002","unstructured":"van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH, Boomsma F (2002) The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 47(1):85\u201394. https:\/\/doi.org\/10.1530\/eje.0.1470085","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1629_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12022-011-9188-1","volume":"23","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Tischler AS, de Krijger RR (2012) Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol 23(1):4\u201314. https:\/\/doi.org\/10.1007\/s12022-011-9188-1","journal-title":"Endocr Pathol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01629-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:16:03Z","timestamp":1641582963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01629-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01629-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was approved by the local Ethical Committee (protocol 2011\/0020149; Careggi Hospital, Florence, Italy).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Appropriate informed consent was acquired from enrolled patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}